دورية أكاديمية
أعرض في EDS

Assessment of adherence to carbamazepine using plasma and saliva samples, a study from Jordan.

التفاصيل البيبلوغرافية
العنوان: Assessment of adherence to carbamazepine using plasma and saliva samples, a study from Jordan.
المؤلفون: Al-Taani GM; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid Jordan., Yehya A; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid Jordan., Albals D; Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan., Alsous M; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid Jordan.
المصدر: Heliyon [Heliyon] 2024 Feb 23; Vol. 10 (5), pp. e26736. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Elsevier Ltd, [2015]-
مستخلص: Background: The measurement of carbamazepine levels in a biological sample is required to guide dosing, and prevent toxicity, and can be useful to assess medication adherence.
Aim: The primary aim of the presented study is to analyze carbamazepine levels in saliva and plasma samples of outpatients and to assess adherence to carbamazepine using saliva and plasma levels.
Methods: Adults who used carbamazepine for at least one month were recruited from the outpatient clinic department of Princess Basma Hospital, a public hospital in Irbid. Saliva and blood samples (1 ml) were collected simultaneously from subjects, and using a microanalytical method with high-performance liquid chromatography coupled with an ultraviolet detector, the level of carbamazepine (in micrograms per milliliter) was ascertained. Analysis of adherence to carbamazepine was carried out using plasma and saliva levels.
Results: A total of 69 consecutive patients attending the neurology clinic were recruited, of whom 85.5% had epilepsy. Approximately one-third (34.8%) used carbamazepine as monotherapy, whereas the remainder used a combination of antiepileptic drugs to control seizures. Overall, about two-thirds (71.9%) of the studied samples were non-adherent in either plasma or saliva samples. By referring to the plasma sample carbamazepine concentration, 75.4% of the respondents were adherents, 15.9% had under-adherence, and 8.7% had over-adherence. A total of 85.9% of the responders were adherent using the carbamazepine level in saliva samples. Plasma and saliva carbamazepine levels were linearly correlated to one another. Polypharmacy was commonly utilized with the patients, as 42% of the patients used two medications, with a range of 1-7 drugs used concomitantly. The predictor associated with higher plasma and saliva carbamazepine levels, as determined by multiple linear regression analysis, was the occurrence of seizures less than once a month, as compared to seizures with higher frequencies.
Conclusion: Saliva carbamazepine levels show the potential to be used as an alternative matrix to assess medication adherence, with a considerable correlation with the plasma carbamazepine level. Healthcare professionals can address routine care non-adherence through such measures.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 The Authors.)
References: Neurol India. 2002 Mar;50(1):60-2. (PMID: 11960153)
Neurosciences (Riyadh). 2011 Jan;16(1):18-23. (PMID: 21206440)
Clin Pharmacokinet. 1992 Nov;23(5):365-79. (PMID: 1478004)
Ther Drug Monit. 1993 Aug;15(4):317-27. (PMID: 8236368)
J Clin Pharm Ther. 2011 Oct;36(5):625-36. (PMID: 21062333)
Methods Find Exp Clin Pharmacol. 2001 Nov;23(9):481-5. (PMID: 11876020)
J Anal Toxicol. 1992 Mar-Apr;16(2):88-92. (PMID: 1501470)
Epilepsy Behav. 2018 Aug;85:205-211. (PMID: 30032809)
Ther Drug Monit. 2016 Jun;38(3):365-70. (PMID: 26818624)
J Econ Perspect. 2017;31(4):125-44. (PMID: 29465217)
Ann Clin Biochem. 1979 Jul;16(4):213-6. (PMID: 533228)
Seizure. 2020 Dec;83:251-263. (PMID: 33334546)
Clin Chem. 1988 Sep;34(9):1863-6. (PMID: 3416433)
Health Qual Life Outcomes. 2003 Aug 28;1:36. (PMID: 14498989)
Clin Chim Acta. 2017 Sep;472:35-40. (PMID: 28713031)
Arch Dermatol. 2004 Apr;140(4):408-14. (PMID: 15096368)
Clin Pharmacokinet. 1999 Jun;36(6):453-70. (PMID: 10427469)
Acta Pharmacol Sin. 2012 Nov;33(11):1431-40. (PMID: 23103621)
Epilepsy Behav. 2002 Aug;3(4):338-342. (PMID: 12609331)
Epilepsia. 2008 Mar;49(3):446-54. (PMID: 18031549)
Biomed Chromatogr. 2002 Feb;16(1):19-24. (PMID: 11816007)
J Med Assoc Thai. 1999 Jan;82(1):80-8. (PMID: 10087743)
Ther Drug Monit. 2013 Feb;35(1):4-29. (PMID: 23288091)
Drugs Aging. 2004;21(12):793-811. (PMID: 15382959)
Pharmaceutics. 2019 Sep 29;11(10):. (PMID: 31569535)
Mater Sociomed. 2015 Jun;27(3):167-71. (PMID: 26236162)
Br J Gen Pract. 2011 Feb;61(583):128-30. (PMID: 21276339)
Int J Neurosci. 2016 Nov;126(11):972-8. (PMID: 26441313)
Seizure. 2017 Dec;53:75-80. (PMID: 29149668)
Anal Chem. 2003 Aug 1;75(15):3731-8. (PMID: 14572037)
J Chromatogr. 1993 Oct 22;620(1):169-73. (PMID: 8106587)
Acta Neurol Belg. 2003 Mar;103(1):19-23. (PMID: 12704979)
Expert Rev Clin Pharmacol. 2018 Jul;11(7):705-718. (PMID: 29898616)
Arch Dis Child. 2017 Apr;102(4):357-361. (PMID: 27799154)
Wellcome Open Res. 2020 Apr 23;5:75. (PMID: 33709037)
Vojnosanit Pregl. 2009 May;66(5):347-52. (PMID: 19489468)
Clin Pharmacokinet. 1990 Apr;18(4):318-28. (PMID: 2182266)
Ther Drug Monit. 1988;10(2):133-43. (PMID: 3289143)
Ther Drug Monit. 1997 Dec;19(6):637-42. (PMID: 9421104)
Int J Med Sci. 2018 May 22;15(8):823-831. (PMID: 30008593)
Acta Anaesthesiol Scand. 2005 Nov;49(10):1540-3. (PMID: 16223403)
J Pharm Biomed Anal. 2021 Apr 15;197:113961. (PMID: 33626445)
فهرسة مساهمة: Keywords: Adherence; Carbamazepine; Compliance; Jordan; Pharmacology
تواريخ الأحداث: Date Created: 20240308 Latest Revision: 20240309
رمز التحديث: 20240309
مُعرف محوري في PubMed: PMC10918113
DOI: 10.1016/j.heliyon.2024.e26736
PMID: 38455560
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-8440
DOI:10.1016/j.heliyon.2024.e26736